The invention relates to monocarbonyl complexes of ruthenium and osmium with bi- and tridentate nitrogen and phosphine ligands. The invention relates to methods for preparing these complexes and the use of these complexes, isolated or prepared in situ, as catalysts for reduction reactions of ketones and aldehydes both via transfer hydrogenation or hydrogenation with hydrogen.

The present invention relates to a process for hydrogenation of a glycerol ester, comprising treating a composition which comprises a glycerol ester with a base and a transition metal catalyst in the presence of molecular hydrogen, wherein the base is present in at least 7 wt % based upon the total weight of said composition and wherein the catalyst is present in less than or equal to 0.05 wt % based upon the total weight of said composition.

The present invention relates to a compound of the following formula (I):

##STR00001##

or a pharmaceutically acceptable salt and/or solvate thereof,
for use as photosensitizer agent in photodynamic therapy.

The present invention relates also to a pharmaceutical composition comprising such a compound and at least one pharmaceutically acceptable excipient.

The present invention relates also to a conjugate comprising such a compound linked to a biomolecule such as a peptide, a protein, an aptamer, an affibody, an antibody or an antigen binding fragment thereof.

A Ruthenium complex containing alkynyl group, a method of synthesizing the Ruthenium complex containing alkynyl group and a use thereof are provided. The Ruthenium complex has a chemical formula of Ru(L).sub.2(DPPZ′). DPPZ′ is a main ligand having structural formula of ##STR00001##
R is any one selected from the group consisting of H, substituted or unsubstituted phenyl, R.sub.1NH.sub.2, R.sub.1OH, and SiMe.sub.3; R.sub.1 is C1-C5 chain alkyl group; L is an auxiliary ligand with N as coordinating atom. Sonogashira coupling reaction is utilized to introduce alkynyl group into a DPPZ-type Ruthenium complex; the introduced alkynyl group is beneficial to promote the transmembrane absorption of drug molecules, increase the probability of drug entry into cells, and can also increase efficacy and reduce toxic and side effects of drugs. The Ruthenium complex provided has significant anti-tumor activity, especially anti-breast cancer activity, and can provide new ideas for designing anti-tumor drug molecules in the future.

The present invention relates to a compound of the following formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, in particular in the treatment of cancer. The present invention also relates to a pharmaceutical composition comprising such a compound and to a method for the preparation of such a compound.

##STR00001##

The invention relates to monocarbonyl complexes of ruthenium and osmium with bi- and tridentate nitrogen and phosphine ligands. The invention relates to methods for preparing these complexes and the use of these complexes, isolated or prepared in situ, as catalysts for reduction reactions of ketones and aldehydes both via transfer hydrogenation or hydrogenation with hydrogen.

The present invention is directed to assay methods and compounds and kits used in such assays.

The present invention relates to the technical field of chiral synthesis, and specifically provides a new type of oxa-spirodiphosphine ligands. The bisphosphine ligand is prepared with oxa-spirobisphenol as a starting material after triflation, palladium catalyzed coupling with diaryl phosphine oxide, reduction of trichlorosilane, further palladium catalyzed coupling with diaryl phosphine oxide, and further reduction of trichlorosilane. The oxa-spiro compound has central chirality, and thus includes L-oxa-spirodiphosphine ligand and R-oxa-spirodiphosphine ligand. The racemic spirodiphosphine ligand is capable of being synthesized from racemic oxa-spirobisphenol as a raw material. The present invention can be used as a chiral ligand in the asymmetric hydrogenation of unsaturated carboxylic acids. The complex of the ligand with ruthenium can achieve an enantioselectivity of greater than 99% in the asymmetric hydrogenation of methyl-cinnamic acid.

Methods for the synthesis of polycyclic aromatic hydrocarbons and synthesis platforms for performing such syntheses are provided. Methods and platforms are provided that allow for the synthesis of aza-polycyclic aromatic hydrocarbons by an expedient ring assembly. Methods and platforms allow for a modular approach to synthesis that provide multiple new C—C bonds in sequential pericyclic reactions, thus giving access to compounds with multiple axes of substitution.

Compositions and methods of capturing one or more nucleic acid molecules of a cell or subcellular compartment are described. In certain aspects, the compositions comprise a caged molecule comprising one or more photolinkers and an antisense oligonucleotide, which when uncaged hybridizes to a target nucleic acid molecule.